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Abstract
Although AL amyloidosis usually is a systemic disease, strictly localized AL deposits are not exceptionally rare. Such
case reports form a considerable body of published articles. Although both AL amyloidosis types are formed from an
N-terminal segment of a monoclonal immunoglobulin light chain, a typical localized AL amyloid differs from the systemic
counterpart by the morphological appearance of the amyloid, and presence of clonal plasma cells and of giant cells. In this
article it is pointed out that localized AL amyloidosis (‘amyloidoma’) represents a true plasma cell neoplasm and not a
pseudotumor. The pathogenesis of localized AL amyloidosis may differ from that of the systemic type, a suggestion underlined
by the fact that localized AL amyloidosis of kappa type is as common as that of lambda origin, in contrast to the systemic form
where lambda chains constitute the overwhelming majority of cases. It is suggested that oligomeric assemblies of the produced
immunoglobulin light chain are toxic to plasma cells, which in this way commit suicide.
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Introduction
The amyloidoses constitute a large and heterogeneous
group of protein misfolding disorders in which pro-
teins adopt a high degree of beta-sheet structure,
allowing molecules to bind to each other in long,
cross-beta-sheet ﬁbrils. In this form the protein is
comparatively resistant to degradation, explaining
why the amyloid masses may increase as long as the
protein substrate is present. The mechanisms behind
the ﬁbril formations are still insufﬁciently understood,
but it is generally accepted that generation of amyloid
from a protein includes three phases. The ﬁrst phase
is nucleation, at which misfolded molecules assemble
to form a nucleus, resembling the process of crysta-
llization (1). This nucleus can catalyze an amyloid-
prone misfolding of other molecules, which adopt
b-structure and form rapidly growing ﬁbrils. This
second elongation phase proceeds until a steady state
(third phase) has been obtained. A particularly favor-
able milieu is consequently formed where there is a
high concentration of substrate.
This mini-review deals with the nature of one
localized form of amyloidosis that clinically often
presents as a malignant tumor but that is often
regarded as a pseudotumor or tumor-like nodule
(2,3). One of the main messages in this communica-
tion is that it is a manifestation of a real neoplasm.
AL amyloidosis
Amyloidosis can either be systemic or localized. In
systemic forms, the precursor of the ﬁbril protein is
expressed at one site, e.g. liver or bone-marrow,
released to blood plasma in soluble form, distributed
via the circulation, and ﬁnally deposited as amyloid
ﬁbrils in different organs by yet unknown mecha-
nisms. In human, 15 different proteins have been
shown to be able to cause systemic amyloidosis,
although most forms are very rare (4). One of the
least uncommon is AL amyloidosis where the ﬁbril
protein is derived from monoclonal immunoglobulin
(Ig) light chains. The primary cause of this form of
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plasma cell expressing one light chain, usually in
excess. The plasma cell clone is spread in the bone-
marrow, either as a malignant tumor (myeloma) or as
apparently benign cells. The Ig light chain circulates
in blood plasma before it aggregates into amyloid
ﬁbrils in virtually all organs outside the brain by so
far unknown mechanisms. Systemic AL amyloidosis
is usually lethal.
Although many of the subclasses of Ig light chains
are represented in amyloid only, not all light chains
are amyloidogenic. There is strong evidence that this
restriction depends on the variability in the amino
acid sequences, and certain variable subgroups and
amino acid substitutions are particularly important
(5,6). AL protein of lambda type is 2–3 times more
common than of kappa type (7,8). The major part of
amyloid AL protein lacks a portion of the constant
region (9-12), although a minor component always
is the complete Ig light chain (13). Whether or not
this truncation is pathogenically important or occurs
after ﬁbrillogenesis is not clear.
Localized AL amyloidosis
Amyloid localized to one tissue, where multiple
deposits appear, is very common, particularly in
association with aging. Examples are amyloid in
the brain in Alzheimer’s disease and in islets of
Langerhans in type 2 diabetes (14). In contrast local-
ized AL amyloidosis usually appears as one, often
tumor-like lesion, although multiple nodules may
occur. The symptoms may vary depending on loca-
tion of the lesion, but, initially, malignant tumors are
often suspected, particularly when the nodules are
present in the breast, lung, or urinary tract (3,15,16).
Calciﬁcations are common (17), and in the case of
breast nodules mammographic appearance may
include microcalciﬁcations, increasing the suspicion
of malignancy (Figure 1) (18,19). A monoclonal
component in plasma is usually absent (20). Treat-
ment of choice seems to be local resections endo-
scopically, although radical excision has been
performed successfully, e.g. for respiratory lesions
(3,21). Local resections often have to be repeated
(22). The long-term prognosis is usually favorable,
although deaths due to severe hemorrhages or other
complications have been described (20,21). While a
monoclonal gammopathy of unknown signiﬁcance
(MGUS) may develop to systemic amyloidosis or
myeloma (23) this does not seem to happen with a
localized plasma cell clone associated with localized
amyloidosis, which almost never progresses to a
systemic disease (20,24,25).
Appearance of localized AL amyloid
Usually, amyloid deposits are observed in a strictly
limited but not encapsulated area. Involvement of
vessel walls is common but does only occur very close
to the main deposit. Like systemic AL amyloidosis,
afﬁnity for Congo red is variable between patients but
always present, as is the concomitant green birefrin-
gence in polarized light. Unlike deposits in most cases
of systemic amyloidosis, crystal-like structures with
Maltese cross appearance are as common as areas
with concentric ring structures (Figure 2). These
formations usually have stronger afﬁnity for Congo
red and a brighter green birefringence. Typically,
scattered and small groups of plasma cells occur in
the amyloid deposits. Localized AL amyloid can
occur at virtually any site of the body, including the
brain (26). Most common sites are eyelids, larynx,
bronchi, skin, and urinary tract.
Biochemical nature of localized AL amyloid
An immunoglobulin light chain nature of localized
nodular pulmonary amyloid was indicated by peptide
mapping and immunodiffusion soon after the mono-
clonal light chain origin of primary systemic amyloid-
osis had been demonstrated (27). Later, amino acid
sequence analyses proved the monoclonal immuno-
globulin light chain nature in a number of cases
(28-35). AL kappa is as common as AL lambda
(Solomon A., personal communication). On very
rare occasions, a heavy chain fragment has been
demonstrated (36). As in systemic AL amyloidosis,
most of the amyloid protein is not full-length light
chain molecules, and a varying part of the constant
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Figure 1. Localized AL amyloidosis in a breast. The localized
nature and occurrence of microcalciﬁcations (arrows) constitute
a risk of misdiagnosis of mammary carcinoma.
Localized AL amyloidosis: A suicidal neoplasm? 245region is missing (27,29,34,35,37). Small amounts of
full-length light chains are usually present as well as
small C-terminal fragments (13). The importance of
fragmentation in the amyloidogenic process is still not
quite settled, since it has been suspected to occur after
ﬁbril formation. On the other hand, the almost uni-
versal predominance of N-terminal fragments over
fragments from the C-terminus has been suggested to
indicate a major mechanism in ﬁbrillogenesis (37).
Is localized AL amyloid a pseudotumor or a real
neoplasm?
According to Celsus a tumor originally meant swell-
ing, but the designation is nowadays almost only
used for neoplasm. Consequently, tumor-like lesions
should be non-neoplastic swellings. It is obvious that
localized AL amyloidosis appears as a tumor accord-
ing to a classical deﬁnition. The descriptions ‘tumor-
like’ or ‘pseudotumor’ are often used in order to
discriminate from neoplasm. This may be correct
for localized AL amyloidosis in the sense that the
mass depends on the deposition of amyloid, but, as
described below, the basic lesion is nevertheless a
neoplasm in the form of a clonal expansion of one
plasma cell.
A localized production of the amyloid immuno-
globulin light chain was suspected at an early date but
was difﬁcult to prove. On most occasions, the plasma
cell clone is very discrete and even difﬁcult to reco-
gnize. Only very exceptionally is the background
a clear-cut immunocytoma or plasmacytoma with
atypia and mitoses (38). Not only is the number of
plasma cells in the amyloid lesion often fairly sparse,
but trials to identify monoclonality of the plasma cells
by immunohistochemistry have also generally failed
(22), although an abnormal overload of kappa or
lambda plasma cells sometimes is evident (Figure 3).
By means of immunohistochemistry it is often evident
that a mixture of plasma cell populations with both
kappa and lambda-expressing cells is present.
A predominance of one plasma cell type (kappa or
lambda) has sometimes been taken as evidence for
monoclonality (39). However, gene rearrangement
analysis of a few typical localized AL amyloidoses
has shown presence of plasma cell clones (40-44).
A similar result was obtained by amino acid sequence
analysis of the deposited amyloid combined with
mRNA extraction and DNA sequencing (33). There-
fore it has been suggested that the process can be
classiﬁed as a ‘low-grade B cell lymphoproliferative
disease’ (44), a somewhat diffuse designation but one
which in hematological terminology probably means a
neoplasm.
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Figure 2. Typical appearance of localized AL amyloidosis with discrete amyloid formation and multiple giant cells. Note the concentric
appearance of some amyloid particles (arrows).
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Figure 3. ‘Amyloidoma’ immunolabeled with the immunoglobulin
light chain lambda-speciﬁc monoclonal antibody pwlam (73). Amy-
loid and a majority of plasma cells (PC) are strongly labeled. Note
the giant cells (GC) between plasma cells and amyloid. The
hypothesis is that plasma cells are synthesizing an amyloidogenic
Ig light chain, which is modiﬁed by giant cells to amyloid ﬁbrils.
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Given that the most common localization of localized
AL amyloidosis is at mucous membranes in contact
with the environment, it has been suggested there is
an antigenic induction of amyloidogenic plasma cell
clones (17). A chronic inﬂammation has often been
encountered (15). It seems likely that similar plasma
cell clones without amyloid deposits may appear as
commonly when the cells do not produce an amyloi-
dogenic Ig light chain. It is noteworthy that a number
of cases with localized AL amyloidosis have been
associated with Sjögren’s syndrome (24,45).
Giant cells in localized AL amyloidosis
Foreign giant cells are very often mentioned in plen-
tiful case reports on localized amyloidosis (e.g.
(17,18,22,36,39,44,46-55)). Their occurrence is usu-
ally explained as a reaction to the amyloid deposits
(54). However, amyloid in general does not induce a
foreign body reaction, and there are almost never any
giant cells present in the amyloid masses in systemic
AL amyloidosis. Furthermore, amyloid ﬁbrils close to
giant cells are organized in the same way as seen at
sites where cells participate in amyloid production,
e.g. in the spleen in AA amyloidosis (56) or in the
islets of Langerhans in IAPP amyloidosis (14). This
is often suggested already when using polarization
microscopy where a clear-cut orientation of amyloid
ﬁbril bundles against giant cells is evident (Figure 4).
Therefore, we proposed that giant cells in localized
AL amyloidosis directly participate in the transfor-
mation of the soluble full-length light chains into
insoluble ﬁbrils formed from N-terminal light chain
fragments (34).
The genesis and function of multinuclear giant
cells, typical of certain infections and inﬂammations,
are still poorly understood. They develop by fusion of
macrophages and are generally thought of as cellular
elements that try to perform phagocytosis of particular
structures, e.g. larger foreign particles. However, this
simplistic explanation has been questioned, and giant
cells may exhibit novel functions that are not yet
understood (57). Experimentally, giant cells have
been reported to be induced by cultivation of mono-
cytes in the presence of interleukin 3 (IL-3) and
interferon-gamma (58,59), IL-4 (60-64), or IL-13
(65). Plasma cells can express IL-4 (66). Although
T cells may be a more important source of IL-4,
there is a normal foreign body response in T cell-
deﬁcient mice (67). The inducer in localized AL
amyloid is unknown, and giant cells do not appear
in the bone-marrow in systemic AL amyloidosis in
spite of presence of neoplastic plasma cells. It should
also be pointed out that the bone-marrow is usually
not particularly affected in the systemic disease,
although the ﬁbril protein is synthesized there.
Hypothesis and conclusion
From the current knowledge, it is only possible to
create a hypothesis for the pathogenesis of localized
AL amyloidosis. A benign small plasma cell clone is
formed at one site, perhaps after prolonged antigenic
stimulation. The clonal plasma cells produce an
immunoglobulin light chain which is amyloidogenic
but needs to be modiﬁed. Only clones that can recruit
macrophages, which fuse to giant cells by mechanisms
yet to be elucidated, can form amyloid. The modiﬁ-
cation of the light chains may take place within giant
cells which take up the soluble light chain molec-
ules by endocytosis and process them so that the
N-terminal parts can aggregate into ﬁbrils. Alter-
natively, protein modiﬁcation may occur on the cell
surface. Most likely, the assembly take place on the
cell surface, e.g. after lysosomal secretion, which is a
regulated secretory pathway (68). Such a scenario
would explain the evident organization of amyloid
ﬁbrils close to giant cells, very different from what
is seen in deposits in systemic amyloidosis. Another
fact which points to a pathogenesis different from
systemic amyloidosis is that localized AL amyloid
of kappa type is common. Although it is only possible
to speculate, this may depend on a lower propensity of
kappa chains to form beta-sheet ﬁbrils, overcome in
the localized situation where the protein concentra-
tionclosetoplasmacellslikelyishigh.Thehypothetical
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Figure 4. Amyloid adjacent to giant cells (GC). An organization of
amyloid ﬁbrils is apparent when in contact with giant cells. This
organization is interpreted as assemblage of protein, probably after
some modiﬁcation, into ﬁbrils on or at the surface of the cells.
Congo red stained section in polarized light with crossed polars.
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outlined in Figure 5.
Another interesting aspect of localized AL amyloid
is the sparse occurrence of plasma cells in the lesions.
In fact, the number of plasma cells is sometimes so
low that the clonality can be difﬁcult to demonstrate.
The lesion has therefore been suggested to represent
a ‘burnt-out’ plasmacytoma (9,69). In many other
amyloid diseases, e.g. Alzheimer’s disease or type
2 diabetes, there is increasing evidence that amyloid
protein aggregation involves genesis of smaller aggre-
gates (oligomers, protoﬁbrils) that exert a toxic effect
on nearby cells and generate apoptosis (reviewed in
(70,71)). In addition, such a mechanism is believed
to explain the rapid effect on myocardial dysfunction
after successful treatment of a plasma cell clone in
systemic AL amyloidosis (72). If generation of toxic
oligomers is true also with the formation of localized
AL amyloid, this may lead to apoptosis of plasma cells
in an ‘amyloidoma’. This event may then be regarded
as a suicide of tumor plasma cells creating a
self-limiting neoplasm.
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